
Microbot Medical (MBOT) Stock Forecast & Price Target
Microbot Medical (MBOT) Analyst Ratings
Bulls say
Microbot Medical Inc has strengthened its financial position through equity financings and option exercises, leading to increased financing income of $284K for the quarter and $611K year-to-date, significantly higher than the previous year. The company is poised for substantial growth with the anticipated full launch of its LIBERTY Endovascular Robotic System in the U.S. in 2Q26, along with further introductions in the EU and other markets, supported by expanded commercial capabilities and positive provider feedback. Additionally, the implementation of a logistics partnership enhances operational readiness, positioning Microbot favorably for accelerated growth and a competitive market advantage.
Bears say
Microbot Medical Inc faces significant risks that contribute to a negative outlook on its stock, including potential delays in the commercialization of its LIBERTY Endovascular Robotic System and challenges in expanding into neuro and cardio markets. The company may experience headwinds related to reimbursement issues and the absence of profitability in the near term, exacerbated by the high cost of the device impacting hospital margins. Additionally, the lack of data from randomized controlled trials and setbacks in securing international regulatory approvals could hinder the company's growth and market adoption.
This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.
Microbot Medical (MBOT) Analyst Forecast & Price Prediction
Start investing in Microbot Medical (MBOT)
Order type
Buy in
Order amount
Est. shares
0 shares